Akeso (9926) Fundamentals 2026 — Revenue Analysis | SniperIQ
Akeso (9926) is a CN-listed Healthcare company in Biotechnology with a market capitalization of HK$91.0B, trading at HK$98.90 on the HKSE. This SniperIQ fundamentals page covers Akeso's valuation, profitability (net margin -36.4%), revenue (¥3.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Akeso's market cap?
Akeso (9926) has a market capitalization of approximately HK$91.0B, trading at HK$98.90 on the HKSE. Market cap moves with the live share price.
What is Akeso's P/E ratio?
Akeso's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 8.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Akeso?
Akeso runs a net profit margin of -36.4%, a gross margin of 78.7%, and an operating margin of -29.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Akeso generate?
Akeso reported revenue of ¥3.0B for fiscal year 2025, with net income of -¥1.1B and earnings per share (EPS) of -1.2. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Akeso pay a dividend?
Akeso does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Akeso financially healthy?
Akeso carries a debt-to-equity ratio of 0.50x and a current ratio of 5.14x, with a market beta of 0.00. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Akeso a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Akeso (9926) the key facts are: market cap HK$91.0B, revenue ¥3.0B, 52-week range 80.2-179. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Akeso's full fundamentals live
Get Akeso's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.